The U.S. Food and Drug Administration approved a low-cost generic version of the HIV prevention shot lenacapavir for use in low-income countries.

Courthouse News, Washington Times, AP + 6 more · United States

3 Nov 20269 outlets

What it means

The U.S. has approved a of the twice-yearly HIV prevention shot , specifically for sale in low-income countries. This generic, manufactured by Dr. Reddy's Laboratories, is priced at roughly $40 per person per year, a dramatic reduction from the brand-name version's U.S. list price of over $28,000 annually. The move aims to expand access to a highly effective (over 99.9% efficacy) prevention tool in regions with the highest HIV burden, though the generic cannot be sold in the U.S. because the brand-name version (Yeztugo, by Gilead Sciences) is still under patent protection there.

Accuracy & sourcesGrounded

The claim is solid, reported by multiple reputable outlets (AP, Reuters, Science, STAT News) citing the FDA approval and Dr. Reddy's as the manufacturer. The reporting sits close to the primary source—the FDA's regulatory action—and is consistent across outlets, with specific pricing and access details corroborated by Gilead's own access strategy page.

The U.S. Food and Drug Administration approved a low-cost generic version of the HIV prevention shot lenacapavir for use in low-income countries.

What it means

Accuracy & sourcesGrounded

How new

Past coverage

Go deeper